Subxiphoid completion thymectomy for refractory non-thymomatous myasthenia gravis

被引:8
|
作者
Ambrogi, Vincenzo [1 ]
Tacconi, Federico [1 ]
Sellitri, Francesco [1 ]
Tamburrini, Alessandro [2 ]
Perroni, Gianluca [3 ]
Carlea, Federica [3 ]
La Rocca, Eleonora [3 ]
Vanni, Gianluca [1 ]
Schillaci, Orazio [4 ]
Mineo, Tommaso Claudio [1 ]
机构
[1] Policlin Tor Vergata Univ, Dept Surg, Div Thorac Surg, Myasthenia Gravis Unit, Rome, Italy
[2] Southampton Gen Hosp, Div Thorac Surg, Southampton, Hants, England
[3] Tor Vergata Univ, Postgrad Sch Thorac Surg, Rome, Italy
[4] Tor Vergata Univ, Dept Biomed & Prevent, Nucl Med Unit, Rome, Italy
关键词
Myasthenia gravis (MG); completion thymectomy; subxiphoid video-assisted thoracic surgery (subxiphoid VATS); acetylcholine receptor antibodies; TRANS-CERVICAL THYMECTOMY; THYMIC TISSUE; REPEAT THYMECTOMY;
D O I
10.21037/jtd.2020.03.81
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Background: Completion thymectomy may be performed in patients with non-thymomatous refractory myasthenia gravis (MG) to allow a complete and definitive clearance from residual thymic tissue located in the mediastinum or in lower neck. Hereby we present our short- and long-term results of completion thymectomy using subxiphoid video-assisted thoracoscopy. Methods: Between July 2010 and December 2017, 15 consecutive patients with refractory non-thymomatous myasthenia, 8 women and 7 men with a median age of 44 [interquartile range (IQR) 38.5-53.5] years, underwent video-thoracoscopic completion thymectomy through a subxiphoid approach. Results: Positron emission tomography (PET) showed mildly avid areas [standardized uptake value (SUV) more than or equal to 1.8] in 11 instances. Median operative time was 106 (IQR, 77-141) minutes. No operative deaths nor major morbidity occurred. Mean 1-day postoperative Visual Analogue Scale value was 2.53 +/- 0.63. Median hospital stay was 2 (IQR, 1-3.5) days. A significant decrease of the anti-acetylcholine receptor antibodies was observed after 1 month [median percentage changes -67% (IQR, -39% to -83%)]. Median follow-up was 45 (IQR, 21-58) months. At the most recent follow-up complete stable remission was achieved in 5 patients. Another 9 patients had significant improvement in bulbar and limb function, requiring lower doses of corticosteroids and anticholinesterase drugs. Only one patient remained clinically stable albeit drug doses were reduced. One-month postoperative drop of anti-acetylcholine receptor antibodies was significantly correlated with complete stable remission (P=0.002). Conclusions: This initial experience confirms that removal of ectopic and residual thymus through a subxiphoid approach can reduce anti-acetylcholine receptor antibody titer correlating to good outcome of refractory MG.
引用
收藏
页码:2388 / 2394
页数:7
相关论文
共 50 条
  • [1] Thymectomy for non-thymomatous myasthenia gravis
    Cea, Gabriel
    Benatar, Michael
    Verdugo, Renato J.
    Salinas, Rodrigo A.
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2013, (10):
  • [2] Comparison of thymomatous and non-thymomatous myasthenia gravis on outcome after thymectomy
    Cabrera-Maqueda, J. M.
    Fuentes Rumi, L.
    Alba Isasi, M. T.
    Vazquez Lorenzo, J.
    Valero Lopez, G.
    Baidez Guerrero, A. E.
    Garcia Molina, E.
    Diaz Perez, J.
    Lopez Sanchez, J.
    Garrnes Sanchez, C. M.
    Arroyo Tristan, A.
    Hernandez Clares, R.
    EUROPEAN JOURNAL OF NEUROLOGY, 2018, 25 : 258 - 258
  • [3] Is thymectomy in non-thymomatous myasthenia gravis of any benefit?
    Diaz, Andres
    Black, Edward
    Dunning, Joel
    INTERACTIVE CARDIOVASCULAR AND THORACIC SURGERY, 2014, 18 (03) : 381 - 389
  • [4] Outcomes after thymectomy in non-thymomatous myasthenia gravis
    Deboever, Nathaniel
    Xu, Ying
    Feldman, Hope A.
    Woodman, Karin H.
    Chen, Merry
    Shih, Ya-Chen Tina
    Rajaram, Ravi
    JOURNAL OF THORACIC DISEASE, 2023, 15 (06) : 3048 - +
  • [5] DISEASE DURATION AND THYMECTOMY IN NON-THYMOMATOUS MYASTHENIA GRAVIS
    Lyou, Hyun Ji
    Chung, Hye Yoon
    Kim, Seung Woo
    Shin, Ha Young
    MUSCLE & NERVE, 2022, 65 : S15 - S16
  • [6] CERVICAL THYMECTOMY FOR NON-THYMOMATOUS MYASTHENIA-GRAVIS
    WHYTE, RI
    DONNELLY, RJ
    THORAX, 1987, 42 (03) : 226 - 226
  • [7] The value of thymectomy in the treatment of non-thymomatous myasthenia gravis
    Menghesha, Hruy
    Schroeter, Michael
    Doerr, Fabian
    Schlachtenberger, Georg
    Heldwein, Matthias B.
    Chiapponi, Costanza
    Wahlers, Thorsten
    Bruns, Christiane
    Hekmat, Khosro
    CHIRURG, 2022, 93 (01): : 48 - 55
  • [8] Effect of thymectomy for late onset non-thymomatous myasthenia gravis
    Kawaguchi, N.
    Kuwabara, S.
    Nemoto, Y.
    Takahashi, H.
    Fukutake, T.
    Arimura, K.
    Osame, M.
    Hattori, T.
    JOURNAL OF NEUROIMMUNOLOGY, 2006, 178 : 231 - 231
  • [9] Minimally Invasive Thymectomy in Non-Thymomatous Myasthenia Gravis Cases
    Ceylan, Kenan Can
    Kaya, Seyda Ors
    Ozturk, Ozgur
    Zorlu, Yasar
    Gedizlioglu, Muhtesem
    EUROPEAN RESPIRATORY JOURNAL, 2017, 50
  • [10] MGTX rationale for the thymectomy trial in non-thymomatous myasthenia gravis
    Wolfe, Gil I.
    JOURNAL OF NEUROIMMUNOLOGY, 2008, 203 (02) : 220 - 220